Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Archival of Human Biological Samples in CU-Med Biobank

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04706481
Recruitment Status : Recruiting
First Posted : January 12, 2021
Last Update Posted : January 12, 2021
Sponsor:
Information provided by (Responsible Party):
Professor Ronald C.W. Ma, Chinese University of Hong Kong

Brief Summary:
CU-Med Biobank collaborates with different researchers for collecting and distributing human biospecimens and clinical data for assisting scientific research.

Condition or disease Intervention/treatment
Healthy Cancer Heart Diseases Neurological Diseases or Conditions Kidney Diseases Diabetes Other Disease Procedure: Specimen Collection

Detailed Description:
CU-Med Biobank will collect and store high-quality specimens from cancer-related or other diseases. All samples are linked to annotated clinical data from approved consented protocols. This system provides researchers with high- quality biological samples and comprehensive clinical, pathological including molecular/genetic information for their research. This standardized CU-Med Biobank is a pivotal bridge to improve the translation of basic research into clinical applications. These findings will contribute to improve prevention, enhance diagnosis, develop new treatment and eventual cure of diseases.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 10000 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 99 Years
Official Title: Archival of Human Biological Samples in CU-Med Biobank
Actual Study Start Date : January 1, 2020
Estimated Primary Completion Date : December 1, 2050
Estimated Study Completion Date : December 1, 2050

Group/Cohort Intervention/treatment
Healthy Control
Healthy subjects who have provided consent for specimen collection
Procedure: Specimen Collection
Specimens obtained from surgical, phlebotomy or other non-invasive procedure

Cancer or Other Diseases
Diseased subjects who have provided consent for specimen collection
Procedure: Specimen Collection
Specimens obtained from surgical, phlebotomy or other non-invasive procedure




Primary Outcome Measures :
  1. To distribute human biospecimens for clinical research [ Time Frame: 99 years ]
    By using the biological samples from CU-Med Biobank, translational studies can be done.

  2. To discover the pathological mechanism of different acute and chronic diseases such as cancer, stroke, heart disease, dementia & diabetes [ Time Frame: 99 years ]
    The relationship between different genome/proteome/bacteriome/virome and various diseases can be revealed, thus leading to a better prognostic and diagnostic outcome.


Biospecimen Retention:   Samples With DNA
Bufft coats, plasma, serum, tissues, pleural effusion, urine and stool, etc


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The diverse group of biorepositories with focus on normal cohorts and cancer-related or other disease cohorts.
Criteria

Inclusion Criteria:

  • Enrolled subjects that have provided signed consent for the specimens and de-identified data to be collected, stored and distributed.

Exclusion Criteria:

  • Subjects without signed informed consent for the specimens and de-identified data to be collected, stored and distributed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04706481


Contacts
Layout table for location contacts
Contact: Terry OR, Ph.D 852-26285221 terryor@cuhk.edu.hk
Contact: Marcus LAW, M. Phil 852-26285221 marcuslaw@cuhk.edu.hk

Locations
Layout table for location information
Hong Kong
CU-Med Biobank Recruiting
Hong Kong, Hong Kong
Contact: Terry Or, PhD    852-26285221    terryor@cuhk.edu.hk   
Contact: Marcus Law, Master    852-26285221    marcuslaw@cuhk.edu.hk   
Sponsors and Collaborators
Chinese University of Hong Kong
Investigators
Layout table for investigator information
Study Chair: Ching Wan MA, MB BChir Chinese University of Hong Kong
Additional Information:
Layout table for additonal information
Responsible Party: Professor Ronald C.W. Ma, Professor, Chinese University of Hong Kong
ClinicalTrials.gov Identifier: NCT04706481    
Other Study ID Numbers: CREC 2019.152
First Posted: January 12, 2021    Key Record Dates
Last Update Posted: January 12, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Professor Ronald C.W. Ma, Chinese University of Hong Kong:
Biobanking
Additional relevant MeSH terms:
Layout table for MeSH terms
Nervous System Diseases
Kidney Diseases
Heart Diseases
Disease
Urologic Diseases
Cardiovascular Diseases
Pathologic Processes